Efficient Drug Delivery to Alveolar Macrophages and Lung Epithelial Lining Fluid Following Pulmonary Administration of Liposomal Ciprofloxacin in Rats with Pneumonia and Estimation of its Antibacterial Effects

The efficacy of pulmonary administration of liposomal ciprofloxacin (CPFX) in pneumonia was evaluated. In brief, the pharmacokinetics following pulmonary administration of liposomal CPFX (particle size, 1,000 nm; dose, 200 μg/kg) were examined in rats with lipopolysaccharide-induced pneumonia as an experimental pneumonia model. Furthermore, the antibacterial effects of liposomal CPFX against the pneumonic causative organisms were estimated by pharmacokinetic/pharmacodynamic (PK/PD) analysis. The time-courses of the concentration of CPFX in alveolar macrophages (AMs) and lung epithelial lining fluid (ELF) following pulmonary administration of liposomal CPFX to rats with pneumonia were markedly higher than that following the administration of free CPFX (200 μg/kg). The time course of the concentrations of CPFX in plasma following pulmonary administration of liposomal CPFX was markedly lower than that in AMs and ELF. These results indicate that pulmonary administration of liposomal CPFX was more effective in delivering CPFX to AMs and ELF compared with free CPFX, and it avoids distribution of CPFX to the blood. According to PK/PD analysis, the liposomal CPFX exhibited potent antibacterial effects against the causative organisms of pneumonia. This study indicates that pulmonary administration of CPFX could be an effective technique for the treatment of pneumonia.

[1]  T. Seki,et al.  Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[2]  R. Curi,et al.  Role of insulin on PGE2 generation during LPS-induced lung inflammation in rats. , 2006, Life sciences.

[3]  T. Seki,et al.  Influence of particle size on drug delivery to rat alveolar macrophages following pulmonary administration of ciprofloxacin incorporated into liposomes , 2006, Journal of drug targeting.

[4]  E. Septimus,et al.  A Retrospective, Comparative Evaluation of Dysglycemias in Hospitalized Patients Receiving Gatifloxacin, Levofloxacin, Ciprofloxacin, or Ceftriaxone , 2005, Pharmacotherapy.

[5]  O. Cars,et al.  Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. , 2005, The Journal of antimicrobial chemotherapy.

[6]  R Wise,et al.  Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492. , 2004, The Journal of antimicrobial chemotherapy.

[7]  Gilbert Greub,et al.  Microorganisms Resistant to Free-Living Amoebae , 2004, Clinical Microbiology Reviews.

[8]  W. Craig,et al.  Pharmacodynamics of the New Des-F(6)-Quinolone Garenoxacin in a Murine Thigh Infection Model , 2003, Antimicrobial Agents and Chemotherapy.

[9]  Y. Hirakata,et al.  In Vivo Efficacy of a New Quinolone, DQ-113, against Streptococcus pneumoniae in a Mouse Model , 2003, Antimicrobial Agents and Chemotherapy.

[10]  Kenichi Sato,et al.  In Vitro and In Vivo Antibacterial Activities of DK-507k, a Novel Fluoroquinolone , 2003, Antimicrobial Agents and Chemotherapy.

[11]  D. Hoban,et al.  Stretching the mutant prevention concentration (MPC) beyond its limits. , 2003, The Journal of antimicrobial chemotherapy.

[12]  I. Shalit,et al.  Immunomodulatory effects of quinolones. , 2003, The Lancet. Infectious diseases.

[13]  D. Armstrong,et al.  Antimicrobial Activities against 84 Listeria monocytogenes Isolates from Patients with Systemic Listeriosis at a Comprehensive Cancer Center (1955-1997) , 2003, Journal of Clinical Microbiology.

[14]  P. Toutain,et al.  The pharmacokinetic-pharmacodynamic approach to a rational dosage regimen for antibiotics. , 2002, Research in veterinary science.

[15]  O. Cars,et al.  Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. , 2002, International journal of antimicrobial agents.

[16]  M. Tanaka,et al.  Inhibitory activity of quinolones against DNA gyrase of Mycobacterium tuberculosis. , 2001, The Journal of antimicrobial chemotherapy.

[17]  A. Templeton,et al.  Effects of sparfloxacin, grepafloxacin, moxifloxacin, and ciprofloxacin on cardiac action potential duration. , 2000, European journal of pharmacology.

[18]  James C. Sacchettini,et al.  Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase , 2000, Nature.

[19]  J. Karhukorpi,et al.  In vitro antibiotic susceptibility of Francisella tularensis isolated from humans and animals. , 2000, The Journal of antimicrobial chemotherapy.

[20]  O. Harb,et al.  From protozoa to mammalian cells: a new paradigm in the life cycle of intracellular bacterial pathogens. , 2000, Environmental microbiology.

[21]  J. Pieters,et al.  A Coat Protein on Phagosomes Involved in the Intracellular Survival of Mycobacteria , 1999, Cell.

[22]  Yasuo Watanabe,et al.  In Vitro and In Vivo Antimicrobial Activities of T-3811ME, a Novel Des-F(6)-Quinolone , 1999, Antimicrobial Agents and Chemotherapy.

[23]  T. Ishida,et al.  Etiology of community-acquired pneumonia in hospitalized patients: a 3-year prospective study in Japan. , 1998, Chest.

[24]  P. Tattevin,et al.  Confusion and general seizures following ciprofloxacin administration. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[25]  G L Drusano,et al.  Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. , 1998, JAMA.

[26]  N. Miyashita,et al.  In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp , 1997, Antimicrobial agents and chemotherapy.

[27]  L. Fisher,et al.  Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones , 1997, Antimicrobial agents and chemotherapy.

[28]  W. Craig.  Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. , 1995, Diagnostic microbiology and infectious disease.

[29]  Jerome J. Schentag,et al.  The Importance of Pharmacokinetic/Pharmacodynamic Surrogate Markers to Outcome , 1995, Clinical pharmacokinetics.

[30]  J J Schentag,et al.  Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients , 1993, Antimicrobial Agents and Chemotherapy.

[31]  H. Neu,et al.  In vitro activity of OPC-17116 , 1992, Antimicrobial Agents and Chemotherapy.

[32]  J. Antonini,et al.  Accumulation of amiodarone and desethylamiodarone by rat alveolar macrophages in cell culture. , 1991, Biochemical pharmacology.

[33]  T. Suga,et al.  Uptake of clarithromycin by rat lung cells. , 1990, The Journal of antimicrobial chemotherapy.

[34]  R. Helmke,et al.  Resistance of mucoid Pseudomonas aeruginosa to nonopsonic phagocytosis by alveolar macrophages in vitro , 1988, Infection and immunity.

[35]  H. Stiver,et al.  Inhibition of polymorphonuclear leukocyte chemotaxis by the mucoid exopolysaccharide of Pseudomonas aeruginosa. , 1988, Clinical and investigative medicine. Medecine clinique et experimentale.

[36]  J. Blaser,et al.  Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance , 1987, Antimicrobial Agents and Chemotherapy.

[37]  R. Crystal,et al.  Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. , 1986, Journal of applied physiology.

[38]  P. Densen,et al.  Phagocyte strategy vs. microbial tactics. , 1980, Reviews of infectious diseases.

[39]  J. Verhoef,et al.  Effect of protein A on staphylococcal opsonization , 1977, Infection and immunity.

[40]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[41]  T. Seki,et al.  Pharmacokinetic and pharmacodynamic efficacy of intrapulmonary administration of ciprofloxacin for the treatment of respiratory infections. , 2007, Drug metabolism and pharmacokinetics.

[42]  H. Blau,et al.  Moxifloxacin but not ciprofloxacin or azithromycin selectively inhibits IL-8, IL-6, ERK1/2, JNK, and NF-kappaB activation in a cystic fibrosis epithelial cell line. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[43]  R. Moore,et al.  Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. , 1987, The Journal of infectious diseases.

[44]  M. Horwitz,et al.  Influence of the Escherichia coli capsule on complement fixation and on phagocytosis and killing by human phagocytes. , 1980, The Journal of clinical investigation.